BCM
EDIT icon

Bayesian Capital Management’s Editas Medicine EDIT Stock Holding History

Bayesian Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,400
Closed -$181K – 835
2024
Q1 		$181K Buy
+24,400
New +$203K 0.02% 666
2023
Q4 		– Sell
-31,200
Closed -$243K – 823
2023
Q3 		$243K Buy
+31,200
New +$268K 0.03% 512
2023
Q2 		– Sell
-16,900
Closed -$123K – 854
2023
Q1 		$123K Sell
16,900
-6,200
-27% -$55.1K 0.02% 662
2022
Q4 		$205K Sell
23,100
-5,700
-20% -$62.6K 0.03% 590
2022
Q3 		$353K Buy
28,800
+5,900
+26% +$91.9K 0.07% 367
2022
Q2 		$271K Buy
+22,900
New +$307K 0.05% 514
2021
Q4 		– Sell
-8,402
Closed -$345K – 420
2021
Q3 		$345K Buy
+8,402
New +$460K 0.1% 239

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bayesian Capital Management's EDIT Position: Q2 2024 in Review

Bayesian Capital Management sold out of Editas Medicine (EDIT) in Q2 2024, closing a stake of 24,400 shares — an estimated $181K sold.

Bayesian Capital Management first reported a position in EDIT in Q3 2021 and held it in 7 quarters. The position peaked at $353K in Q3 2022. 235 funds tracked by Wall St. Rank hold EDIT as of Q2 2024.

  • Bayesian Capital Management reported no remaining Editas Medicine position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 24,400 Editas Medicine shares in Q2 2024, an estimated $181K.
  • Bayesian Capital Management first reported a position in Editas Medicine in Q3 2021 and held it in 7 quarters.
  • Bayesian Capital Management's Editas Medicine position peaked at $353K in Q3 2022.
  • 235 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.